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New insights into lipid metabolism in the nephrotic syndrome. VLDL triglyceride levels are independent of the rate of
Hyperlipidemia in the nephrotic syndrome results from in- synthesis of VLDL apoB 100 in nephrotic humans [1] but
creased synthesis and decreased catabolism of lipoproteins. are inversely correlated to the fractional rate of VLDLThe contribution of each to establishing blood lipid levels is
catabolism, suggesting a catabolic defect causes increasedunknown. Increased triglyceride rich lipoprotein concentra-
VLDL.tion, very low density lipoprotein (VLDL) and intermediate
density lipoprotein (IDL) primarily results from decreased
clearance. This defect is due in part to reduced lipoprotein
REDUCED CATABOLISM CAUSESlipase (LPL) on the vascular endothelium resulting either from
decreased synthesis or inadequate binding of this enzyme to INCREASED VLDL
endothelial surfaces. In contrast, both low density lipoprotein
The principal determinants of VLDL catabolism are(LDL) and lipoprotein(a) [Lp(a)] concentrations are increased.
endothelial bound lipoprotein lipase (LPL) and avail-Unlike the case of albumin or transferrin, or apoA-I in the
rat, LDL apoB 100 synthesis is not related to that of albumin, ability of apolipoprotein C-II (apoC-II), a small apolipo-
suggesting a different mechanism of regulation or a response protein necessary for full LPL activity [5]. Although total
to a stimulus that is not the same as that augmenting the plasma apoC-II is normal in nephrotic patients its con-
synthesis of nonlipoproteins. Evidence is presented for synthe-
centration is reduced by more than 50% per unit ofsis of LDL through a mechanism that bypasses the normal
VLDL, since VLDL is increased but apoC-II is not [6].delipidation pathway that requires a VLDL precursor for LDL
formation. HDL concentration is normal but maturation is While there is a relative reduction in the local concentra-
impaired leading to a shift from the larger HDL2 to the smaller tion of apoC-II relative to VLDL, the most notable
HDL3, a variant that is less effective as a transporter of the change in the components of lipolysis is a decrease in
LPL cofactor apolipoprotein C II.
the endothelial bound LPL pool [7] (abstract; Shearer
et al, J Am Soc Nephrol 9:622A, 1998).
Lipoprotein lipase (LPL) tethers triglyceride rich lipo-
The nephrotic syndrome is characterized by the loss
proteins to the vascular endothelium [9] and is the rate
into the urine of proteins of intermediate molecular
limiting enzyme for lipolysis. Garber et al suggested that
weight. Decreased albumin concentration causes de-
reduced LPL activity was responsible for delayed lipoly-
creased plasma colloid oncotic pressure (p). In contrast,
sis in nephrotic rats [10]. Recently, mRNAs encoding
the concentration of a number of high molecular weight
the VLDL receptor [11], LPL and hepatic lipase (HL)
proteins, including lipoproteins, is increased.
[12] have all been found to be reduced in tissues of
Hyperlipidemia in nephrotic patients is characterized
nephrotic rats. However, it is not clear what role these
by increased very-low density lipoprotein (VLDL), low
changes play in establishing the size of the biologically
density lipoprotein (LDL) [1], lipoprotein a [Lp (a)]
active LPL pool or in altering VLDL catabolism. Lipoly-
[2] levels with little change in high density lipoprotein
sis of chylomicrons in vitro by hearts isolated from ne-
(HDL), and results from increased synthesis and de-
phrotic rats is decreased and the LPL pool bound to the
creased fractional clearance of lipoproteins [1, 3]. While
vascular endothelium reduced by approximately 90%,
VLDL synthesis may be increased in some nephrotic
while tissue bound LPL was normal [7] (abstract; Shearer
patients [1], VLDL levels increase predominately be-
et al, J Am Soc Nephrol 9:622A, 1998). Thus reduction
cause of decreased VLDL clearance in both nephrotic
specifically of the endothelial bound LPL pool may be
patients [1] and rats [4]. VLDL apoB 100 levels and
responsible for reduced VLDL and chylomicron (CM)
catabolism.
Lipoprotein lipase (LPL) is synthesized in mesenchy-Key words: Lp(a), apoB 100, VLDL, LDL, HDL, lipase, lipoprotein
synthesis, catabolism, fibrinogen. mal tissue such as adipose tissue, and muscle cells, is
secreted and is then released [13]. It then tethers to 1999 by the International Society of Nephrology
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Fig. 1. Metabolism of liver derived lipoproteins. Very-low density lipoprotein (VLDL) is secreted by the liver and then hydrolyzed on the vascular
endothelium by low density lipoprotein (LPL). Lipoprotein lipase (LPL) is bound electrostatically to heparan sulfate and, in the presence of
apolipoprotein C-II (apoC-II) hydrolyzes triglycerides (TG). LPL is important in binding of VLDL to the vascular endothelium and VLDL
receptor. Surface constituents of VLDL, free cholesterol and phospholipids participate in the formation of nascent high density lipoprotein (HDL).
Free cholesterol on the surface of nascent HDL is esterified by lecithin cholesterol acyltransferase (LCAT) to form cholesterol esters. These sink
into the core as nascent HDL is converted to HDL3, and finally into cholesterol ester (CE) rich HDL2. The TG depleted VLDL remnant particle
is released and then either taken up by liver directly via the remnant receptor, which recognizes apo E, or interacts with CE rich HDL2. In that
interaction, catalyzed by cholesterol ester transfer protein (CETP), the CE rich core of HDL2 is exchanged for the TG rich core of the VLDL
remnant, yielding a TG rich HDL molecule (not shown) and LDL, which is then taken up by the liver through the LDL receptor. HDL2 is
processed by lipase to HDL3 to continue the cycle. LDL also may be synthesized directly, thorough pathways other than delipidation of VLDL.
This is evident in some nephrotic patients. Synthesis of both LDL and Lp(a) are increased in nephrotic patients. Broken lines connote pathways
believed to have increased synthesis in nephrotic patients.
vascular endothelium binding to heparan sulfate. It is Nevertheless, the marked diminution of this critical pool
there that LPL encounters lipoproteins (Fig. 1). Synthe- of LPL activity is far in excess of what should be expected
sis and release of LPL may not be impaired in mesenchy- if there was a decrease in synthesis on the order of magni-
mal tissues (abstract; Shearer et al, J Am Soc Nephrol tude of what would expected from the decreased levels
9:622A, 1998), but instead decreased lipolysis may be a of mRNA [12].
consequence of depletion specifically of the endothelial
bound LPL pool necessary for endothelial binding of
ALTERATION IN HDL MATURATIONVLDL and for normal lipolysis. A specific decrease in
High density lipoprotein (HDL) shuttles apoC-II fromthis lipase pool may be due to a defect in tethering of
remnant particles to VLDL and chylomicrons (CMs) [5].the protein to the endothelium, or to labilization of its
Normal VLDL and CM catabolism therefore requiresattachment there. The mechanism responsible for deple-
tion of the endothelial bound LPL pool is unknown. the presence of normally functioning HDL. Maturation
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of HDL to HDL2, the form that most effectively trans- although hypoalbuminemia may specifically augment se-
cretion of apoB by reduced binding of oleic acid andports apoC-II, requires lecithin:cholesterol acyltransfer-
ase (LCAT), an enzyme that may not function ade- other free fatty acids [17].
quately in the nephrotic syndrome because of reduced
binding of lysolecithin by albumin, as a result of hypoal-
LIPOPROTEIN(a) LEVELS ARE INCREASED ASbuminemia (Fig. 1) [14]. In the nephrotic syndrome in
A RESULT OF INCREASEDhumans the fraction of HDL in the higher molecular
SYNTHESIS ALONEweight HDL2 is reduced and replaced by an increase
Lipoprotein(a) [Lp(a)] consists of a molecule of LDLin the lower molecular weight HDL3 isoform. This is
to which one molecule of the apolipoprotein apo(a) hasprecisely the distribution expected should LCAT activity
been covalently attached to apoB 100. The size of apo(a)be reduced. This change would reduce reverse choles-
in Lp(a) is genetically determined [25], and its syntheticterol transport and favor atherogenesis [15]. These
rate varies inversely with molecular weight of the isoformchanges in HDL maturation could also play a role in
encoded. Individuals having the largest apo(a) isoformsdecreasing lipolysis of triglyceride rich lipoproteins as a
have the lowest levels. Lp(a) levels increase in nephroticconsequence of less effective apoC-II cycling by HDL3.
patients independently of isoform [2] and decrease dur-
ing remission. Lp(a) concentration is increased as a result
LDL SYNTHESIS IS INCREASED, BUT NOT of increased synthesis alone, in contrast to all of the
COORDINATELY WITH ALBUMIN other lipoproteins in nephrotic patients [26].
Since VLDL synthesis is not increased [1] (abstract; It is not yet known what biological significance in-
Shearer et al, J Am Soc Nephrol 9:622A, 1998), and there creased levels of Lp(a) has in this setting. Lp(a) is a
is impedance in the conversion of VLDL to its products powerful atherosclerotic risk factor when it occurs genet-
including LDL, one would assume that LDL synthesis ically. However, these high Lp(a) concentrations occur
would not be increased. This, however, is not the case in combination with low molecular weight isoform. Thus,
[1]. While direct hepatic secretion of LDL is possible, it is difficult to know whether it is the concentration
the bulk of apoB 100 secreted by the liver is in VLDL or the specific isoform of Lp(a) present that promotes
[16]. LDL then arises from modification of secreted atherogenesis. Recently studies suggest that low molecu-
VLDL as depicted in Figure 1. We observed that in lar weight isoform per se may confer atherosclerotic risk
some nephrotic patients synthesis of LDL apoB 100 was [27].
actually greater than VLDL apoB 100, suggesting that Therefore, the nephrotic syndrome is characterized by
increased LDL synthesis in the nephrotic syndrome oc- a change in the lipoprotein concentrations and composi-
curred in part by an alternate pathway bypassing the tion. Triglyceride rich lipoproteins, VLDL, CMs and
normal delipidation pathway. This pathway for LDL syn- remnant particles are increased primarily by decreased
thesis (Fig. 1) would allow for increased LDL synthesis catabolism, in large part a result of reduction in endothe-
with no increase in VLDL synthesis and reduced VLDL lial bound LPL. Both LDL and Lp(a) are increased by
catabolism. Activity of cholesterol ester transfer protein increased synthesis. LDL synthesis may be augmented
(CETP), an enzyme that catalyzes the exchange of the through a pathway bypassing its normal precursor; VLDL.
cholesterol ester rich core of HDL2 for the triglyceride
(TG) rich core of VLDL remnant particles yielding LDL ACKNOWLEDGMENTS
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